GV returned for SpyBiotech's $32.5m series A round, as it looks to move its first potential vaccine into the clinic by early next year.
UK-based vaccine developer SpyBiotech received $32.5m yesterday in a series A round featuring internet technology conglomerate Alphabet’s GV unit.
Braavos Investment Advisers led the round, participating alongside Oxford Sciences Innovation (OSI), Oxford Investment Consultants and the UK government-owned Future Fund, which converted an existing loan.
Spun out of University of Oxford in 2017, SpyBiotech is working on technology that will facilitate the safe delivery of vaccines while increasing efficacy, and is focusing on infectious and chronic diseases as well as…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
